IT1164730B - Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori - Google Patents

Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori

Info

Publication number
IT1164730B
IT1164730B IT50529/79A IT5052979A IT1164730B IT 1164730 B IT1164730 B IT 1164730B IT 50529/79 A IT50529/79 A IT 50529/79A IT 5052979 A IT5052979 A IT 5052979A IT 1164730 B IT1164730 B IT 1164730B
Authority
IT
Italy
Prior art keywords
beta
aglycone
activity
radio
tumour cells
Prior art date
Application number
IT50529/79A
Other languages
English (en)
Italian (it)
Other versions
IT7950529A0 (it
Inventor
Adolf W Schwimmer
Irwin Steven Schwartz
David Rubin
Original Assignee
Adolf W Schwimmer
Irwin Steven Schwartz
David Rubin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/951,270 external-priority patent/US4424348A/en
Priority claimed from US05/951,269 external-priority patent/US4584368A/en
Priority claimed from US06/011,619 external-priority patent/US4327074A/en
Application filed by Adolf W Schwimmer, Irwin Steven Schwartz, David Rubin filed Critical Adolf W Schwimmer
Publication of IT7950529A0 publication Critical patent/IT7950529A0/it
Application granted granted Critical
Publication of IT1164730B publication Critical patent/IT1164730B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2334/00—O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IT50529/79A 1978-10-13 1979-10-11 Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori IT1164730B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US05/951,270 US4424348A (en) 1978-10-13 1978-10-13 Methods of manufacture of nitrile-containing glucuronic acid conjugates
US05/951,269 US4584368A (en) 1978-10-13 1978-10-13 β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production
US06/011,619 US4327074A (en) 1978-10-13 1979-02-12 Method for diagnosis and selective treatment of infections of bacteria having β-glucuronidase activity

Publications (2)

Publication Number Publication Date
IT7950529A0 IT7950529A0 (it) 1979-10-11
IT1164730B true IT1164730B (it) 1987-04-15

Family

ID=27359461

Family Applications (1)

Application Number Title Priority Date Filing Date
IT50529/79A IT1164730B (it) 1978-10-13 1979-10-11 Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori

Country Status (12)

Country Link
JP (1) JPS55500837A (enExample)
AU (1) AU534068B2 (enExample)
CA (1) CA1148086A (enExample)
CH (1) CH652724A5 (enExample)
DE (1) DE2953223T1 (enExample)
FR (2) FR2440374B1 (enExample)
GB (1) GB2055044B (enExample)
IL (1) IL58352A (enExample)
IT (1) IT1164730B (enExample)
NL (1) NL7920107A (enExample)
SE (1) SE461983B (enExample)
WO (1) WO1980000791A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490523A (en) * 1981-11-10 1984-12-25 Ely J. Rubin Mandelonitrile triacetyl glucuronate and process for preparing same
AU594855B2 (en) * 1988-01-15 1990-03-15 Baker Norton Pharmaceuticals, Inc. Glucuronic acid derivatives of opioid antagonists
DE59610819D1 (de) * 1995-03-30 2003-12-18 Werner Kreutz Arzneistoffe zur selektiven bekämpfung von tumorgewebe
WO2014138723A2 (en) * 2013-03-08 2014-09-12 Cognate3 Llc Physical optimization beverage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB788855A (en) * 1953-06-30 1958-01-08 Ernst Theodore Krebs Improvements in or relating to mandelo-nitrile-glucuronosides and method of making the same
US2985664A (en) * 1957-05-29 1961-05-23 Ernst T Krebs Hexuronic acid derivatives
US3758455A (en) * 1970-05-14 1973-09-11 Chugai Pharmaceutical Co Ltd Reof mycophenolic acid glucuronide and the process for the preparation the
DE2212014A1 (de) * 1971-04-21 1972-10-26 Deutsche Akademie der Wissenschaf ten zu Berlin, χ 1199 Berlin Verfahren zur fermentativen Spaltung von Transportformen von Chemotherapeutika, insbesondere Cancerostatica
USRE29465E (en) * 1972-08-14 1977-11-01 Eli Lilly And Company Psoriasis treatment with mycophenolic acid
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3959253A (en) * 1973-07-02 1976-05-25 Merck & Co., Inc. β-D-glucosyluronic acid derivatives
JPS5325534A (en) * 1976-08-24 1978-03-09 Rikagaku Kenkyusho Mandelic acid glucosides and their anti-cancerous preparations

Also Published As

Publication number Publication date
IT7950529A0 (it) 1979-10-11
WO1980000791A1 (en) 1980-05-01
SE461983B (sv) 1990-04-23
GB2055044B (en) 1983-04-20
IL58352A (en) 1985-11-29
JPS55500837A (enExample) 1980-10-23
AU534068B2 (en) 1984-01-05
DE2953223C2 (enExample) 1989-05-18
FR2440374B1 (fr) 1986-03-21
AU5112079A (en) 1981-04-16
CA1148086A (en) 1983-06-14
NL7920107A (nl) 1980-08-29
DE2953223T1 (de) 1980-11-27
SE8004369L (sv) 1980-06-12
GB2055044A (en) 1981-02-25
FR2449284A1 (fr) 1980-09-12
FR2440374A1 (fr) 1980-05-30
CH652724A5 (de) 1985-11-29

Similar Documents

Publication Publication Date Title
Cheung et al. N7: A novel multi‐modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age
Geddes et al. Clinical and bacteriological studies with clindamycin
DE68914365D1 (de) Topische metronidazol-formulationen und deren verwendung als arzneimittel.
Yamada et al. Radiosensitizing effect of 5-aminolevulinic acid in colorectal cancer in vitro and in vivo
ES2033021T3 (es) Agente con efecto destructivo a tumores malignos, procedimiento para su obtencion y preparacion para la aplicacion en la terapia de enfermos de cancer.
Kelly et al. Effects of irradiation on nucleic acid formation.
IT1164730B (it) Preparati farmaceutici a base di glucuronidi procedimento per produrli e loro impiego contro tumori
Wiseman et al. Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy
Hirasawa et al. Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis
NL167691C (nl) Werkwijze ter bereiding of vervaardiging van therapeutische preparaten ter verzachting en opheffing van pijnen van verschillende oorsprong, alsmede ter behandeling van reumatische, artritische en andere ontstekingsziekten, waarbij men een werkzame stof in een voor therapeutische toepassing geschikte toedieningsvorm brengt, alsmede een werkwijze voor het bereiden van imidazoolverbindingen en de farmaceutisch aanvaardbare additiezouten daarvan, geschikt voor toepassing bij deze werkwijze.
RU94035764A (ru) Способ лечения онкологического заболевания
HOSHINO et al. SUMMATION OF CARCINOGENIC EFFECT OF 4-NITRO-QUINOLINE 1-OXIDE AND β-RAYS
Kadar et al. Isoproterenol metabolism in children after intravenous administration
Hale et al. The effect of cobalt-60 gamma radiation on passive immunity
Wong 2109 Is combination radiotherapy chemotherapy (RTCT) superior to radiotherapy (RT) alone in the non-surgical management of localized esophageal carcinoma? A meta analysis
Powell et al. Effect of drugs on vitamin B12 levels obtained using the Lactobacillus leichmanii method
Lelieveld et al. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors. VI. BCNU
Wassberg et al. A study of the antibacterial activity of some complex aluminum salts
Grunberg et al. The Mechanism of the Topical Effect of Penicillin G in Experimental Local Streptococcal Infections
Anand et al. A modified technique for the detection of antibiotic synergism
Machulkin et al. Bimodal fluorescent conjugate based on prostate-specific membrane antigen ligands with the chelating agent DOTA and SulfoCy5 dye: synthesis, radiolabeling, and biological activity
Sous et al. Bactericidal activity of phenoxymethylpenicillin in an in-vitro model simulating tissue kinetics
Bisgard et al. Effect of X-ray Irradiation upon bacterial toxemia in rabbits
Roeslin et al. Regional immunotherapy in resectable squamous cell lung carcinoma: analysis of a randomized study
Chakmverty et al. Hospital. Westgate Road, Newcastle-upon-l) we. Scott Med J